Evidence-based approach to the treatment of esophagogastric junction tumors  

作　　者：Francisco Schlottmann María A Casas Daniela Molena 

机构地区：[1]Department of Surgery,Hospital Alemán of Buenos Aires,Buenos Aires C1118AAT,Argentina [2]Department of Surgery,Memorial Sloan Kettering Cancer Center,New York,NY 10065,United States

出　　处：《World Journal of Clinical Oncology》2022年第3期159-167,共9页世界临床肿瘤学杂志（英文版）

摘　　要：The incidence of esophagogastric junction(EGJ)adenocarcinoma is increasing in developed nations due to the rising prevalence of obesity and gastroesophageal reflux disease.Due to the peculiar location in a histological transition zone between the esophagus and the stomach,the management of EGJ tumors is controversial.Two main surgical approaches exist:total gastrectomy with distal esophagectomy or esophagectomy by either transhiatal or transthoracic approach.These operations differ significantly in the extent of lymphadenectomy.In addition,patients with locally advanced disease can receive either preoperative chemoradiation or perioperative chemotherapy.This evidence-based review analyzes current evidence regarding the management of EGJ tumors in order to help defining the best surgical and systemic treatment of these patients.

关 键 词：Esophagogastric junction tumors ESOPHAGECTOMY GASTRECTOMY Esophageal adenocarcinoma CHEMOTHERAPY CHEMORADIATION 

分 类 号：R735[医药卫生—肿瘤]